← Back to headlines
Arbutus Biopharma's Imdusiran Receives FDA Fast Track Designation
Arbutus Biopharma (ABUS) has been granted FDA Fast Track designation for its drug Imdusiran, accelerating its development and review process.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
